Navigation Links
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:4/1/2015)... 1, 2015  For many businesses and industries just ... the case, having the right management software can be ... better than software solutions company TraxStar Technologies , ... the company announced the release of the newest version ... "QATrax ...
(Date:4/1/2015)... , April 1, 2015  The U.S. Food ... Sense4Baby™ wireless maternal/fetal monitoring system ... by pregnant patients to self-administer non-stress tests (NST). ... the FDA for use accompanied by medical professionals. ... European Commission in 2013 for self-administration, including the ...
(Date:4/1/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... medical paper has been published describing the positive ... with severe dry eye.  The results met key ... stated that statistically significant differences in both signs ... at various time points throughout the study.  Of ...
Breaking Medicine Technology:TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 3AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 4RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... Md., Dec. 19, 2011 Medical imaging has revolutionized healthcare ... injury and disease. Modern equipment and protocols ensure that ... possible amounts of radiation, while still providing accurate results ... imaging and any medical procedure must be balanced with ...
... CAMBRIDGE, Mass., Dec. 19, 2011 At universities, ... ethics review boards tasked with overseeing the protection ... to improve the quality of reviews and research ... tremendous obligation from federal regulation and face intense pressure from ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 3IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 4
(Date:4/1/2015)... BC (PRWEB) April 01, 2015 Dr ... announced that she is now offering her patients an ... services. Patients can participate in “Beauty Days”, which is ... by Dr Roz Kamani’s Kitsilano Skin Care Clinic. It ... directly tell patients about the latest products and services ...
(Date:4/1/2015)... 2015 OSF Saint Paul Medical Center, ... , was welcomed into the Ministry April 1, 2015, ... Paul E. Showalter, vicar general of the Catholic Diocese ... culminated a nearly year-long transition process for the former ... Speakers for the morning ceremony included Sister Judith Ann ...
(Date:4/1/2015)... 01, 2015 Like a mosaic slowly ... scientific understanding of the potential causes of rosacea. April ... National Rosacea Society (NRS) to educate the public on ... disorder now estimated to affect more than 16 million ... research on rosacea through its patient-funded research grants program, ...
(Date:4/1/2015)... April 01, 2015 eMindful , ... expansion of its executive team with the addition of ... officer. , In his new role, Suissa ... user interface across the business and consumer portals. He ... building the company’s online community. His hiring was ...
(Date:4/1/2015)... When annoying or concerning skin conditions ... weeks for an appointment with a dermatologist is the ... appointments haven’t been possible within dermatology. However, in the ... noticed demand for this level of service and are ... relief or answers to dermatological issues are to our ...
Breaking Medicine News(10 mins):Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 3Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2
... UK has found a new theory from the results of ... wide for children’s to prevent// from Tuberculosis infection is also ... infection. The researchers studied the risk factors involved for TB ... scar, as the absence of BCG scar implies that the ...
... plants, our teeth and gums are photosensitive says an ... of Periodontology. The paper authored by a researcher at ... that sunlight is an important factor in the maintenance ... are important to oral health," observed study author Charles ...
... a man to achieve or maintain an erection sufficient for ... men experience this at some point in their lives//, usually ... Some men, however, experience chronic, complete ED (impotence), and often ... study in the October 18 issue of the Journal of ...
... fish has been proved with evidence following the finding that ... of three to four years. The research adds to the ... sharp//. ,Previous findings have established that consumption of ... Alzheimer’s disease and stroke. Fish such as salmon and tuna ...
... the next issue of the British Dental Journal says that ... satisfactory when the existing methods that are usually employed in ... used to clean and disinfect the roots during a root ... from 25 general dental practices in the UK and found ...
... bird flu from Turkey and Romania have alerted the ... meet of European Union ministers to coordinate decisions on fighting ... told France 2 television: “This is an animal epidemic. The ... has arrived at our doorstep," ,Tests have detected ...
Cached Medicine News:Health News:BCG vaccine for both Protection and treatment of Tuberculosis 2Health News:Sunlight For Healthy Gums And Teeth 2Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: